Geri
Adaptimmune Therapeutics PLC (ADAP) Fiyatı
ADAP Hisse Senedi Fiyat Grafiği
ADAP Finansal
Adaptimmune Therapeutics PLC
$0.04
-3%
$0
Bugün itibarıyla:Jan 20, 13:33:03 GMT-5
Gelir
Bilanço
Nakit akışı
Yıllık
Çeyrek yıllık
ADAP Gelir
Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Follow-Up Questions
Adaptimmune Therapeutics PLC'in temel mali tabloları nelerdir?
ADAP'ün temel finansal oranları nelerdir?
Adaptimmune Therapeutics PLC'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Adaptimmune Therapeutics PLC kârlı mı?
Adaptimmune Therapeutics PLC'in herhangi bir yükümlülüğü var mı?
Adaptimmune Therapeutics PLC'in tedavüldeki hisse sayısı kaçtır?
Önemli İstatistikler
Önceki Kapanış
$0.05
Açılış fiyatı
$0.0425
Günün Aralığı
$0.0425 - $0.0599
52 haftalık aralık
$0.0202 - $0.685
İşlem hacmi
1.6M
Ort.Hacim
64.4M
EPS (TTM)
-0.11
Dividend yield
--
Piyasa Değeri
$12.8M
ADAP nedir?
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved